has announced positive topline results from the EPICS-III Phase 2(b)/3 trial of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC). 📌 Why this matters: Promising data strengthens Zydus’ specialty drug pipeline Potential new treatment for a rare chronic liver disease Positions Zydus as a strong innovator in hepatology

#StockInNews#WatchOutFor

1 like